The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …

Introduction 2.1. Tissue Factor (TF)-dependent activation of coagulation system 2.2.
Endothelial cells (ECs) directed Hemostasis 2.3. Virus life cycle 2.4. TLRs expression …

There has clearly been a deluge of international press coverage of the recent outbreak of
Ebolavirus in Africa and is partly related to the “fear factor” that comes across when one is …

Cocktails of monoclonal antibodies (MAbs) that target the surface glycoprotein (GP) of Ebola
virus (EBOV) are effective in nonhuman primate models and have been used under …

There is an increasing frequency of reports regarding the persistence of the Ebola virus
(EBOV) in Ebola virus disease (EVD) survivors. During the 2014–2016 West African EVD …

West Africa is currently in the midst of the largest Ebola outbreak in history. Although there
have been no Ebola virus disease cases identified in the United States, two US health care …

Ebola causes severe hemorrhagic fever in humans and nonhuman primates, and there are
currently no approved therapeutic countermeasures. The virulence of Ebola virus (EBOV) …

The search for a universal filovirus vaccine that provides protection against multiple filovirus
species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and …

Interferons (IFN) are key cytokines with multifaceted antiviral and cell-modulatory properties.
Three distinct types of IFN are recognized (I–III) based on structural features, receptor usage …

Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fatal
hemorrhagic disease in Africa. The biggest outbreak on record is the 2013–2016 epidemic …